Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NASDAQ:ELDN OTCMKTS:EXDI NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.91+1.1%$2.06$0.55▼$6.19$148.12M2.99206,856 shs111,484 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsEXDIExactus$0.00$0.04▼$0.27$38.94M4.2183,144 shs257,300 shsMISTMilestone Pharmaceuticals$1.96+2.6%$1.70$0.63▼$2.75$162.34M0.61.08 million shs1.98 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology+1.06%+1.60%+6.70%+29.93%+13.02%ELDNEledon Pharmaceuticals-4.72%-10.70%-6.92%-15.68%-5.47%EXDIExactus0.00%0.00%0.00%0.00%0.00%MISTMilestone Pharmaceuticals+2.62%+8.89%+12.64%+18.79%+35.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.91+1.1%$2.06$0.55▼$6.19$148.12M2.99206,856 shs111,484 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsEXDIExactus$0.00$0.04▼$0.27$38.94M4.2183,144 shs257,300 shsMISTMilestone Pharmaceuticals$1.96+2.6%$1.70$0.63▼$2.75$162.34M0.61.08 million shs1.98 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology+1.06%+1.60%+6.70%+29.93%+13.02%ELDNEledon Pharmaceuticals-4.72%-10.70%-6.92%-15.68%-5.47%EXDIExactus0.00%0.00%0.00%0.00%0.00%MISTMilestone Pharmaceuticals+2.62%+8.89%+12.64%+18.79%+35.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.0057.07% UpsideELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00313.22% UpsideEXDIExactus 0.00N/AN/AN/AMISTMilestone Pharmaceuticals 2.40Hold$4.50129.59% UpsideCurrent Analyst Ratings BreakdownLatest EXDI, ELDN, CTOR, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MISTMilestone PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.009/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/AEXDIExactus$2.07M0.00N/AN/A($0.09) per share0.00MISTMilestone Pharmaceuticals$1M166.58N/AN/A$0.25 per share7.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius OncologyN/AN/A0.00∞N/AN/A-51.93%-22.17%N/AELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)EXDIExactus-$9.46MN/AN/AN/AN/AN/A-3,272.69%-185.29%N/AMISTMilestone Pharmaceuticals-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%11/11/2025 (Estimated)Latest EXDI, ELDN, CTOR, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/12/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18-$0.20-$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AEXDIExactusN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.120.350.02ELDNEledon PharmaceuticalsN/A8.128.12EXDIExactusN/A1.320.82MISTMilestone Pharmaceuticals4.064.974.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%ELDNEledon Pharmaceuticals56.77%EXDIExactus0.12%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%ELDNEledon Pharmaceuticals12.30%EXDIExactus65.00%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A78.37 million74.79 millionN/AELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableEXDIExactus30599.01 million209.65 millionNot OptionableMISTMilestone Pharmaceuticals3084.99 million68.42 millionOptionableEXDI, ELDN, CTOR, and MIST HeadlinesRecent News About These CompaniesWells Fargo Initiates Coverage of Milestone Pharmaceuticals (MIST) with Overweight RecommendationSeptember 12 at 5:42 AM | msn.comWells Fargo & Company Initiates Coverage on Milestone Pharmaceuticals (NASDAQ:MIST)September 12 at 2:42 AM | americanbankingnews.comMilestone Pharmaceuticals initiated with an Overweight at Wells FargoSeptember 11 at 11:07 AM | msn.comPropel Bio Management LLC Acquires New Stake in Milestone Pharmaceuticals Inc. $MISTSeptember 2, 2025 | marketbeat.comStonepine Capital Management LLC Reduces Stock Holdings in Milestone Pharmaceuticals Inc. $MISTAugust 26, 2025 | marketbeat.comMilestone® Pharmaceuticals to Present at Upcoming ConferencesAugust 19, 2025 | globenewswire.comResearch Analysts Set Expectations for MIST Q3 EarningsAugust 17, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Posts Earnings Results, Misses Expectations By $0.02 EPSAugust 14, 2025 | marketbeat.comMilestone Pharmaceuticals Advances CARDAMYST with FDA and Financial BoostAugust 13, 2025 | theglobeandmail.comMilestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)August 12, 2025 | msn.comMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateAugust 12, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comUS FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal sprayJuly 14, 2025 | pharmabiz.comPMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comWhy Is Milestone Pharmaceuticals Stock Plunging On Friday?July 11, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Jackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Should You Join Buffett and Invest in Constellation Brands?By Jordan Chussler | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025EXDI, ELDN, CTOR, and MIST Company DescriptionsCitius Oncology NASDAQ:CTOR$1.91 +0.02 (+1.06%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.91 0.00 (0.00%) As of 09/12/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Eledon Pharmaceuticals NASDAQ:ELDN$2.42 -0.12 (-4.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.50 +0.08 (+3.31%) As of 09/12/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Exactus OTCMKTS:EXDIExactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.Milestone Pharmaceuticals NASDAQ:MIST$1.96 +0.05 (+2.62%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.96 0.00 (-0.26%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
